We are leaders in Long-Acting Drug Delivery Technology
Our focus is clear. We are working to continue to develop and commercialize pharmaceutical-grade innovative products that set an excellent standard of care in protecting laboratory animal welfare.
Fidelis understands the ethical and scientific importance of providing the highest-quality analgesics to protect the welfare of laboratory animals and limit variability in research results.
Research CapabilitiesFidelis has developed a research platform with proprietary extended-release technology proven to provide up to 72 hours of therapeutic levels (clinical analgesia) with one injection. This technology is triple patent-protected.
Learn more about our Premier Product – Ethiqa XR®
Important Safety Information
For Rats and Mice:
Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression.
Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans.